000112188 001__ 112188
000112188 005__ 20240319080958.0
000112188 0247_ $$2doi$$a10.3390/cancers14071828
000112188 0248_ $$2sideral$$a128327
000112188 037__ $$aART-2022-128327
000112188 041__ $$aeng
000112188 100__ $$aMorote, Juan
000112188 245__ $$aMultiparametric Magnetic Resonance Imaging Grades the Aggressiveness of Prostate Cancer
000112188 260__ $$c2022
000112188 5060_ $$aAccess copy available to the general public$$fUnrestricted
000112188 5203_ $$aWe sought to find further evidence showing the increase in PCa aggressiveness as PI-RADS score increases from four surrogates of PCa aggressiveness: i. prostate biopsy GG (≤3 vs. >3), ii. type of pathology in surgical specimens (favourable vs. unfavourable), iii. clinical stage (localised vs. advanced), and risk of recurrence of localised PCa after primary treatment (low-intermediate vs. high). A group of 692 PCa patients were diagnosed after 3-T multiparametric MRI (mpMRI) and guided and/or systematic biopsies, showing csPCa (GG ≥ 2) in 547 patients (79%) and insignificant PCa (iPCa) in 145 (21%). The csPCa rate increased from 32.4% in PI-RADS < 3 to 95.5% in PI-RADS 5 (p < 0.001). GG ≥ 3 was observed in 7.6% of PCa with PI-RADS < 3 and 32.6% in those with PI-RADS > 3 (p < 0.001). Unfavourable pathology was observed in 38.9% of PCa with PI-RAD < 3 and 68.3% in those with PI-RADS > 3 (p = 0.030). Advanced disease was not observed in PCa with PI-RADS ≤ 3, while it existed in 12.7% of those with PI-RADS > 3 (p < 0.001). High-risk recurrence localised PCa was observed in 9.5% of PCa with PI-RADS < 3 and 35% in those with PI-RADS > 3 (p = 0.001). The PI-RADS score was an independent predictor of all surrogates of PCa aggressiveness as PSA density. We confirmed that mpMRI grades PCa aggressiveness.
000112188 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/PI20/01666
000112188 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000112188 590__ $$a5.2$$b2022
000112188 592__ $$a1.312$$b2022
000112188 591__ $$aONCOLOGY$$b72 / 241 = 0.299$$c2022$$dQ2$$eT1
000112188 593__ $$aOncology$$c2022$$dQ1
000112188 593__ $$aCancer Research$$c2022$$dQ2
000112188 594__ $$a7.4$$b2022
000112188 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000112188 700__ $$0(orcid)0000-0003-0178-4567$$aBorque-Fernando, Angel$$uUniversidad de Zaragoza
000112188 700__ $$aTriquell, Marina
000112188 700__ $$aCelma, Anna
000112188 700__ $$aRegis, Lucas
000112188 700__ $$aMast, Richard
000112188 700__ $$ade Torres, Inés M.
000112188 700__ $$aSemidey, María E.
000112188 700__ $$aSantamaría, Anna
000112188 700__ $$aPlanas, Jacques
000112188 700__ $$0(orcid)0000-0002-3007-302X$$aEsteban, Luis M.
000112188 700__ $$aTrilla, Enrique
000112188 7102_ $$11013$$2817$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Urología
000112188 773__ $$g14, 7 (2022), 1828 [9 p.]$$pCancers$$tCancers$$x2072-6694
000112188 8564_ $$s619453$$uhttps://zaguan.unizar.es/record/112188/files/texto_completo.pdf$$yVersión publicada
000112188 8564_ $$s2647704$$uhttps://zaguan.unizar.es/record/112188/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000112188 909CO $$ooai:zaguan.unizar.es:112188$$particulos$$pdriver
000112188 951__ $$a2024-03-18-13:54:03
000112188 980__ $$aARTICLE